The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has posted a draft1 of its annual 2025 GOLD Report [pdf] on COPD diagnosis, management, and prevention. The report is the second update of the 2023 GOLD Report on COPD, which was the fifth major revision of the report.
For the 2025 report, the GOLD Science Committee conducted systematic literature searches and a double-blind review to include key peer-reviewed research publications from January 2023 to July 2024. As a result, a total of 164 new references have been added to the 2025 version.1
Some key updates and changes for this year’s report, according to the draft document on the GOLD website, include:1
- Chapter 6 on the topic of COVID-19 and COPD has now been removed from the GOLD report.
- Three new figures have been introduced for 2025:
- New Figure 2.6 ‘Pre- and Post- Bronchodilator Spirometry’
- New Figure 3.22 ‘Management of Patients Currently on LABA+ICS’
- New Figure 5.1 ‘Treatable Traits in Pulmonary Hypertension-COPD (PH-COPD) & Suggested Management’
- The following figures have been edited or updated:
- Figure 3.6 ‘Vaccination for Stable COPD’ has been updated with the latest vaccination recommendations
- Figure 3.9 ‘Follow-up Pharmacological Treatment’ has been updated to add information about new treatments ensifentrine and dupilumab
- Figure 3.18 ‘Maintenance Medications in COPD’ has been updated and ensifentrine and dupilumab have been included
- Figure 4.11 ‘Interventions that Reduce the Frequency of COPD Exacerbations’ has had dupilumab added. Page 1 of 8 iv. dupilumab added.
Read the full report [pdf] at the GOLD website.
Editor’s note: this article will be updated when the final 2025 GOLD Report is made available by the organization.
Reference
- Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report. Global Initiative for Chronic Obstructive Lung Disease [DRAFT]. 2024. https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-12Nov2024_WMV-Draft.pdf
